Samsung Electronics, Harvard Medical School Affiliate MGH to Study GLP-1 Treatment Effects Using Galaxy Watch

MT Newswires Live
05/28

Samsung Electronics (KRX:005930) and Harvard Medical School affiliate Massachusetts General Hospital (MGH) will jointly track and analyze physical changes in patients taking glucagon-like peptide-1 (GLP-1) class treatments with the help of the Galaxy Watch.

GLP-1 is an intestinal hormone that helps regulate blood sugar and suppress appetite, Samsung Electronics said in a Thursday release.

The study will assess whether data from the Galaxy Watch 8 and Samsung Health can help manage muscle loss in patients who take GLP-1 drugs by tracking body composition, activity, and heart rate, according to the release.

Shares of Samsung Electronics fell over 2% at market close.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10